Trazodone

證據等級: L5

預測適應症: 10 個

Trazodone: From Major Depressive Disorder to Obsessive-Compulsive Disorder

One-Sentence Summary

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) originally developed and marketed for major depressive disorder. The TxGNN model predicts it may also be effective for Obsessive-Compulsive Disorder (OCD), with 1 historical placebo-controlled RCT and 19 supporting publications (mostly older case reports, cohorts, and reviews), but no currently registered clinical trials.

Quick Overview

Item	Content
Original Indication	Major Depressive Disorder (per literature: trazodone is “an antidepressant that is FDA-approved for the treatment of depression”)
Predicted New Indication	Obsessive-Compulsive Disorder
TxGNN Prediction Score	99.95%
Evidence Level	L2
US Market Status	✗ Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed, structured mechanism-of-action data for trazodone is not available in the current evidence pack. Based on information extracted from the supporting literature, trazodone acts primarily as a 5-HT2A/5-HT2C receptor antagonist combined with weak serotonin transporter (SERT) inhibition — a pharmacological class known as a Serotonin Antagonist and Reuptake Inhibitor (SARI). This distinguishes it from classical SSRIs, though it still modulates central serotonergic tone.

OCD is understood to involve dysregulation of the cortico-striato-thalamic circuit, with serotonin playing a central pathophysiological role — this is the basis for OCD’s well-established preferential response to serotonin reuptake inhibitors (SRIs) such as clomipramine, fluoxetine, fluvoxamine, and paroxetine. Because trazodone also engages the serotonergic system, a mechanistic rationale for anti-obsessional activity exists, and this is reflected in decades of case reports and small trials exploring trazodone as an adjunct or alternative in SRI-refractory OCD.

However, the mechanistic link is not strong or consistent. The bulk of the literature (case reports, small cohorts, one PET-imaging correlation study) positions trazodone as a second-line or augmentation option for patients who have failed clomipramine/SSRIs, not as a primary evidence-based treatment. The only controlled trial identified — a double-blind, placebo-controlled study (Pigott et al., 1992) — investigated trazodone’s antiobsessional efficacy directly, but does not by itself establish robust efficacy. Overall, the biological plausibility is reasonable but the clinical evidence base remains thin and dated.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1629380	1992	RCT	J Clin Psychopharmacol	Double-blind, placebo-controlled trial evaluating trazodone’s serotonin-reuptake-inhibiting properties as a potential antiobsessional treatment in OCD patients, following earlier positive case reports and open trials.
27744763	2017	Review	Postgrad Med	Review of trazodone’s mechanism, formulation, dosage, and adverse effects, summarizing its use in approved (MDD) and non-FDA-approved conditions including OCD.
8993077	1996	Review	Psychopharmacol Bull	Reviews mono- and polypharmacotherapy of OCD; notes OCD as a diagnosis responds almost exclusively to serotonin reuptake inhibitors (SRIs).
8134850	1994	Review	South Med J	Reviews pharmacologic management of OCD, discussing the serotonin/dopamine dysregulation hypothesis underlying SRI-based treatment.
8331098	1993	Review	J Clin Psychiatry	Reviews biological approaches to treatment-resistant OCD, including augmentation of SRIs with other serotonergic agents.
2119885	1990	Cohort	Clin Neuropharmacol	Trazodone given to 9 clomipramine/lithium-resistant OCD patients; group showed mild but significant improvement, with 3 patients responding favorably and relapsing on drug withdrawal.
3501130	1987	Cohort	Psychopathology	PET study showing trazodone-associated OCD symptom improvement correlated with changes in caudate nucleus glucose metabolism.
6703152	1984	Case Report	Am J Psychiatry	Early case report describing trazodone use in obsessive-compulsive disorder.
4009160	1985	Case Report	J Nerv Ment Dis	Two treatment-refractory patients with OCD and comorbid depression showed rapid improvement in both symptom domains on trazodone.
29343875	2017	Case Report	Riv Psichiatr	Prolonged-release trazodone used to treat the depressive phase in a patient with bipolar II disorder and comorbid OCD.

US Market Information

Trazodone currently has no registered NDA and is not marketed under this profile (Market Status: Not Marketed; Total Licenses: 0). No license records are available to summarize.

Safety Considerations

Please refer to the package insert for safety information. Detailed key warnings, contraindications, and drug-drug interaction data are not available in the current evidence pack (flagged as a Blocking data gap: TFDA/FDA label warnings and contraindications have not yet been retrieved).

Conclusion and Next Steps

Decision: Hold

Rationale: The only controlled trial (Pigott et al., 1992) is small, decades old, and does not provide a robust efficacy signal; the remaining evidence consists largely of dated case reports, small cohorts, and reviews. Combined with the absence of any current marketing authorization, MOA data, or safety/DDI information, the evidence base is insufficient to move beyond a research question at this stage.

To proceed, the following is needed:

Retrieval of official label warnings and contraindications (DG001, Blocking) before any S1 safety review can proceed
Confirmed mechanism-of-action data from DrugBank or equivalent source (DG002)
A modern, adequately powered RCT or systematic review replicating/updating the 1992 trial in OCD
Drug-drug interaction data, particularly relevant given trazodone’s known serotonergic and CYP3A4-related interaction potential in current SRI/SSRI-treated OCD populations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.